Market Overview

TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track

TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track

H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE.

Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk Chronic Lymphocytic Leukemia (CLL).

Related Link: OnoSec Sees A Wider Loss Than Expected In Q4 While ImmunoPulse Trial Remains On Track

The company lowered enrollment from 200 to 120 in Part 1 of the study with overall response rate (ORR) endpoint, and dropped the 330-patient Part 2 of the study with progression free survival (PFS) endpoint.

“Based on the last two quarterly updates, we were mostly aware of the enrollment challenges faced by this study, and we welcome the changes to the protocol that the company elected to put in place,” analyst Andrew Fein wrote in a note.

“In our view, it is interesting to instead take a step back and consider what the former SPA of the 2-part study actually meant: the FDA is willing to accept ORR for accelerated approval (satisfied by Part 1 of GENUINE, still ongoing), and then would also like to see PFS in order to grant full approval,” Fein continued.

However, the analyst acknowledged that the amendments introduce a new element of risk to the GENUINE program and reduced his probability of success assigned to this program to 40 percent from 50 percent.  Fein now projects a U.S. launch for 1101 in 2H19 (previously 2H18), followed by launch in the EU one year later.

As such, the analyst cut his price target to $18 from $22.

At the time of writing, shares of TG Therapeutics rose 3.07 percent to $7.06.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for TGTX

Dec 2020HC Wainwright & Co.MaintainsBuy
Oct 2020Cantor FitzgeraldMaintainsOverweight
Sep 2020JP MorganInitiates Coverage OnOverweight

View More Analyst Ratings for TGTX
View the Latest Analyst Ratings


Related Articles (TGTX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration FDA Best of Benzinga

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at